about
Effects of FTY720 on Heart and Lung Functions in Healthy VolunteersEfficacy and Safety of FTY720 for Acute StrokeA 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodEfficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying TherapySafety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisEffect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple SclerosisSafety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying TherapiesFingolimod -Response According to Coping - EvaluationFingolimod Versus Interferon Beta 1b in Cognitive SymptomsBiomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisBioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of FingolimodEfficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients (2005-05-31)Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients (2004-11-30)Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients (2003-04-30)Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant (2005-01-31)Fingolimod in COVID-19
P4844
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2Development of small-molecule inhibitors of sphingosine-1-phosphate signalingInsights into the pharmacological relevance of lysophospholipid receptors.A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.Translational aspects of sphingosine 1-phosphate biology.Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathwaysCYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosisBZM055, an iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distributionDelayed fingolimod-associated asystole[Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations]
P921
Q61922357-1D9B17D9-DD00-4683-9C7C-F904D8AAB812Q61969138-BCAC2805-936A-47A0-8B38-950EA51A08C5Q63315534-8393E7D4-63F3-4B12-8571-D5D4FB9AB5D6Q63317980-7284F0E3-4597-4ECB-B55C-B745881016F4Q63318297-AFAB2EE6-B5E0-4BE5-ABE1-81FF5A5F716FQ63318847-C87B6052-AE8C-41FB-984C-1093FA96E038Q63320704-13E2D64D-4658-4220-BC60-339060E7A586Q63322200-296B9999-BB73-4340-B4F6-7270F269FA3BQ63322343-3264FA3F-4995-4F91-921C-6931E0FC22F3Q63336830-0554699A-C766-471C-B05D-920B70CFABBFQ63339366-F0310FC6-2E16-4F3B-8439-935EEBC4DD2FQ63593395-67F560EF-3C17-46D8-9E00-334323DEC30AQ86246885-7A3D5500-1BFD-494A-9EAA-8DD526A58A82Q86246914-463AA3BD-EA62-4080-A079-02765A9B05BAQ86246942-88CDF420-7483-40DD-9F91-7372901BE86AQ86249883-CF4073B2-3B52-4E74-A86B-F6F55C431220Q87076197-95D26C3B-5F51-4181-891E-BD2DDA82A649
P4844
Q34174973-2C6B6A0F-3F32-402C-820B-F551262F5CA0Q35182894-05A63451-840D-48C6-868F-77FD3B087CA8Q35489007-C24CCF3C-F974-4FAA-9BB8-45A08D36CEB6Q35853199-7A60D568-3030-4ED1-A246-450DF8D99D3EQ36960355-6976D262-57F3-4F88-8224-42ECD21B8A04Q37851885-7BFE8BAA-0FFA-4862-A39D-B4D42D562AB2Q37868165-BD3D7895-3CA1-4D6A-AD58-340407EE9D4BQ39624007-2D155B89-A70D-414F-9DFE-BC2B157283E0Q42733227-65D969ED-6940-47E1-9FF1-74CBF161F14BQ64978550-E99C9015-FE0F-48F2-A06F-B69270B93DBFQ82283384-5D1708A9-5492-4DDC-934D-3257A68A9AA3Q82283387-F38A2C00-E5C1-40B7-8BC4-6ACD7F69B455Q83328499-B2EA0094-94DD-4174-B03A-2B2280FD9CF5Q84302624-022C6457-7673-4DB8-94CC-27915D4A89B7Q84774110-71C9FCBB-8A6D-41FF-9EE7-2C482EE7AE4D
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
fingolimod hydrochloride
@en
type
label
fingolimod hydrochloride
@en
altLabel
2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride
@en
2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride
@en
FTY-720
@en
FTY720
@en
Fingolimod HCl
@en
prefLabel
fingolimod hydrochloride
@en
P486
P592
P661
P662
P665
P683
P1579
P2067
P231
162359-56-0
P232
P233
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
P234
1S/C19H33NO2.ClH/c1-2-3-4-5-6- ...... 2,21-22H,2-8,13-16,20H2,1H3;1H
P235
SWZTYAVBMYWFGS-UHFFFAOYSA-N
P2566
100.205.740
P274
C₁₉H₃₄ClNO₂
P3117
DTXSID00167364
P3345
P3780
P4168
P486
D000068876